Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29648839 | 1.00 | GABRA1 (0.46) | GABRA1GABRB2CYP3A4CA2TRPA1 | |
| SCHEMBL8673334 | 0.88 | CYP3A4 (0.41) | GABRA1GABRB2CYP3A4CA2TRPA1 | |
| SCHEMBL75037 | 0.84 | GABRA1 (0.43) | GABRA1GABRB2CYP3A4TRPA1NPSR1 | |
| SCHEMBL1854136 | 0.83 | CYP3A4 (0.39) | GABRA1GABRB2CYP3A4TRPA1 | |
| SCHEMBL374209 | 0.82 | GABRA1 (0.56) | GABRA1GABRB2CYP3A4CA2TRPA1 | |
| SCHEMBL11415288 | 0.81 | GABRA1 (0.46) | GABRA1GABRB2CYP3A4CA2NLRP3 | |
| SCHEMBL1133364 | 0.76 | GABRA1 (0.50) | GABRA1GABRB2CYP3A4CA2TRPA1 | |
| SCHEMBL28201284 | 0.76 | GABRA1 (0.50) | GABRA1GABRB2CYP3A4CA2TRPA1 | |
| SCHEMBL30520271 | 0.75 | CYP3A4 (0.63) | GABRA1GABRB2CYP3A4CA2TRPA1 | |
| SCHEMBL11351266 | 0.75 | GABRA1 (0.50) | GABRA1GABRB2CA2TRPA1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713378-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NodThera Limited (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NodThera Limited (GB) | 2025-03-11 | — | — | US | disclosed |
| EP-3774961-B1 | ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024236000-A1 | ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS | COVESTRO DEUTSCHLAND AG (DE) | 2024-11-21 | — | — | WO | disclosed |
| EP-4464727-A1 | ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-11-20 | — | — | EP | disclosed |
| US-20240150515-A1 | Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers | COVESTRO DEUTSCHLAND AG (DE) | 2024-05-09 | — | — | US | disclosed |
| EP-4298140-A1 | LOW VISCOSITY CATALYST COMPOSITIONS FOR PRODUCING ISOCYANURATE POLYMERS | Covestro Deutschland AG (DE) | 2024-01-03 | — | — | EP | disclosed |
| CN-111356680-B | Selective inhibitors of NLRP3 inflammasome | 诺瑟拉有限公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-116917364-A | Low viscosity catalyst composition for producing isocyanurate polymers | 科思创德国股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| WO-2001019390-A1 | COMBINATION TREATMENT WITH IL-1RA AND DIARYL SULPHONYL UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | disclosed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0973936-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS | ELI LILLY AND COMPANY (US) | 2000-01-26 | — | — | EP | disclosed |
| WO-1999067221-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0964849-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1999-12-22 | — | — | EP | disclosed |
| US-5942387-A | Combinatorial process for preparing substituted thiophene libraries | ELI LILLY AND COMPANY (US) | 1999-08-24 | — | — | US | disclosed |
| WO-1998046786-A1 | COMBINATORIAL LIBRARIES OF PEPTIDOMIMETIC AMINOTHIOETHER ACIDS | ELI LILLY AND COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998032733-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| EP-0816309-A1 | Scavenger assisted combinatorial process for preparing libraries of urea and thiourea compounds | ELI LILLY AND COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247011-B2 | Selective inhibitors of NLRP3 inflammasome | NLRP3, NOD1, NLRP1 | GABRA1 2922/4885GABRB2 2882/4885CYP3A4 2832/4885 |
| US-20250223263-A1 | SELECTIVE INHIBITORS OF NLRP3 INFLAMMASOME | NLRP3, NOD1, NLRP1 | GABRA1 2922/4885GABRB2 2882/4885CYP3A4 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.